129 related articles for article (PubMed ID: 16456813)
1. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism.
Ibrahim R; Frederickson H; Parr A; Ward Y; Moncur J; Khleif SN
Cancer; 2006 Mar; 106(5):1065-77. PubMed ID: 16456813
[TBL] [Abstract][Full Text] [Related]
2. Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer.
Zhou JH; Chen HZ; Ye F; Lu WG; Xie X
Oncol Rep; 2006 Aug; 16(2):307-11. PubMed ID: 16820908
[TBL] [Abstract][Full Text] [Related]
3. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.
Reesink-Peters N; Hougardy BM; van den Heuvel FA; Ten Hoor KA; Hollema H; Boezen HM; de Vries EG; de Jong S; van der Zee AG
Gynecol Oncol; 2005 Mar; 96(3):705-13. PubMed ID: 15721415
[TBL] [Abstract][Full Text] [Related]
4. FasL expression in colorectal carcinoma and its significance in immune escape of cancer.
Tong Q; Liu K; Wang G
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(1):79-81. PubMed ID: 16711013
[TBL] [Abstract][Full Text] [Related]
5. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction.
Lai HC; Lin WY; Lin YW; Chang CC; Yu MH; Chen CC; Chu TY
Gynecol Oncol; 2005 Oct; 99(1):113-8. PubMed ID: 15996722
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
[TBL] [Abstract][Full Text] [Related]
9. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of apoptosis-related protein 3 is highly associated with tumorigenesis and progression of cervical squamous cell carcinoma.
Zhang Y; Li Q; Huang W; Zhang J; Han Z; Wei H; Cui J; Wang Y; Yan W
Hum Pathol; 2013 Mar; 44(3):388-93. PubMed ID: 23036366
[TBL] [Abstract][Full Text] [Related]
11. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.
Sun T; Zhou Y; Li H; Han X; Shi Y; Wang L; Miao X; Tan W; Zhao D; Zhang X; Guo Y; Lin D
J Exp Med; 2005 Oct; 202(7):967-74. PubMed ID: 16186185
[TBL] [Abstract][Full Text] [Related]
12. Expression of the cell cycle regulator p27(Kip1) in normal squamous epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma of the uterine cervix. Immunohistochemistry and functional aspects of p27(Kip1).
Shiozawa T; Shiohara S; Kanai M; Konishi I; Fujii S; Nikaido T
Cancer; 2001 Dec; 92(12):3005-11. PubMed ID: 11753978
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
14. Effects of FasL expression in oral squamous cell cancer.
Fang L; Sun L; Hu FF; Chen QE
Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
Das H; Koizumi T; Sugimoto T; Chakraborty S; Ichimura T; Hasegawa K; Nishimura R
Br J Cancer; 2000 May; 82(10):1682-8. PubMed ID: 10817504
[TBL] [Abstract][Full Text] [Related]
16. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
17. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
18. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
Satchell AC; Barnetson RS; Halliday GM
Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of immune escape in renal cell carcinoma].
Zheng J; Sun X; Chen J; Jiang F; Li W; Xie S
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):24-6. PubMed ID: 11977630
[TBL] [Abstract][Full Text] [Related]
20. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
